Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other EventsItem 8.01.Other Events.
On August2, 2017, Agile Therapeutics,Inc. (“Agile”) updated its corporate presentation that it intends to use in connection with presentations at conferences and meetings with investors.
A copy of Agile’s presentation is attached hereto as Exhibit99.1 and is hereby incorporated by reference herein.
Item 8.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
|
Description
|
99.1
|
Agile Therapeutics,Inc. Presentation.
|
AGILE THERAPEUTICS INC ExhibitEX-99.1 2 a17-18496_3ex99d1.htm EX-99.1 Exhibit 99.1 A Forward Thinking Womens Health Company NASDAQ: AGRX 1 Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include forward-looking statements. We may,…To view the full exhibit click here
About Agile Therapeutics,Inc. (NASDAQ:AGRX)
Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.